产品
编 号：F755349
分子式：C24H22ClFN6O3
分子量：496.92
分子式：C24H22ClFN6O3
分子量：496.92
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2750707-05-0
产品详情
生物活性：
MRIA9 is an ATP-competitive, pan Salt-Inducible kinase (SIK) and PAK2/3 inhibitor, with IC50 values of 516 nM, 180 nM and 127 nM for SIK1, SIK2 and SIK3, respectively.
体内研究：
MRIA9 shows high oral bioavailability (F = 75-80%).
体外研究：
MRIA9 (5 μM) MRIA9 sensitizes SKOV3 cells to paclitaxel treatment through inducing pronounced apoptosis.MRIA9 (5 μM) with paclitaxel (2 nM) significantly enhances cell death in HeLa cells.MRIA9 strongly impedes centrosome function, causes mitotic spindle mispositioning in ovarian cancer cell lines, prevents the centrosome disjunction during the late G2 phase, and sensitized ovarian cancer cells and patient derived 3D-spheroids to paclitaxel treatment.
MRIA9 is an ATP-competitive, pan Salt-Inducible kinase (SIK) and PAK2/3 inhibitor, with IC50 values of 516 nM, 180 nM and 127 nM for SIK1, SIK2 and SIK3, respectively.
体内研究：
MRIA9 shows high oral bioavailability (F = 75-80%).
体外研究：
MRIA9 (5 μM) MRIA9 sensitizes SKOV3 cells to paclitaxel treatment through inducing pronounced apoptosis.MRIA9 (5 μM) with paclitaxel (2 nM) significantly enhances cell death in HeLa cells.MRIA9 strongly impedes centrosome function, causes mitotic spindle mispositioning in ovarian cancer cell lines, prevents the centrosome disjunction during the late G2 phase, and sensitized ovarian cancer cells and patient derived 3D-spheroids to paclitaxel treatment.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备